These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Akhondzadeh S; Safarcherati A; Amini H Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232 [TBL] [Abstract][Full Text] [Related]
26. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Leucht S; Davis JM; Engel RR; Kissling W; Kane JM Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961 [TBL] [Abstract][Full Text] [Related]
28. Prediction of "natural" course, relapse and prophylactic response in schizophrenic patients. Pietzcker A; Gaebel W Pharmacopsychiatria; 1983 Nov; 16(6):206-11. PubMed ID: 6141577 [TBL] [Abstract][Full Text] [Related]
29. [Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication]. Steuber H; Kind J; Lohrengel S; Müller P Arzneimittelforschung; 1978; 28(9):1492-3. PubMed ID: 38806 [TBL] [Abstract][Full Text] [Related]
30. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. Schennach-Wolff R; Möller HJ; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M Pharmacopsychiatry; 2010 Nov; 43(7):245-51. PubMed ID: 20927697 [TBL] [Abstract][Full Text] [Related]
31. [Treatment of schizophrenia from the viewpoint of the patient. Studies on the course of treatment and neuroleptic treatment from a personal perspective]. Windgassen K Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1989; 58():1-169. PubMed ID: 2576099 [No Abstract] [Full Text] [Related]
33. Outcome in males with first-episode schizophrenia: 7-year follow-up. Ceskova E; Prikryl R; Kasparek T World J Biol Psychiatry; 2011 Feb; 12(1):66-72. PubMed ID: 21087079 [TBL] [Abstract][Full Text] [Related]
34. Do negative symptoms respond to pharmacological treatment? Kane JM; Mayerhoff D Br J Psychiatry Suppl; 1989 Nov; (7):115-8. PubMed ID: 2575914 [No Abstract] [Full Text] [Related]
35. Ideal and reality of neuroleptic relapse prevention. Kissling W Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363 [No Abstract] [Full Text] [Related]
36. The current unsatisfactory state of relapse prevention in schizophrenic psychoses--suggestions for improvement. Kissling W Clin Neuropharmacol; 1991; 14 Suppl 2():S33-44. PubMed ID: 1684309 [TBL] [Abstract][Full Text] [Related]
37. Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials. Sarin F; Wallin L; Widerlöv B Nord J Psychiatry; 2011 Jun; 65(3):162-74. PubMed ID: 21563994 [TBL] [Abstract][Full Text] [Related]
38. Apomorphine's antipsychotic activity. Schaffer MH; Davis JM; Tamminga CA Arch Gen Psychiatry; 1985 Sep; 42(9):927-8. PubMed ID: 2864035 [No Abstract] [Full Text] [Related]
39. Intermittent vs maintenance medication in schizophrenia. Two-year results. Herz MI; Glazer WM; Mostert MA; Sheard MA; Szymanski HV; Hafez H; Mirza M; Vana J Arch Gen Psychiatry; 1991 Apr; 48(4):333-9. PubMed ID: 1672588 [TBL] [Abstract][Full Text] [Related]